MedPath

Endoscopic Resection plus BÂRRX Radiofrequency Ablation for Eradication of Barrett's Mucosa containing High-Grade Dysplasia and Early Cancer. First European Multi-Centre Cohort Study.

Completed
Conditions
Barrett's cancer, Barrett's dysplasia, Barrett's esophagus, Radiofrequency ablation, Endoscopic mucosa resection, Barrett's neoplasia, Endoscopic resection
Registration Number
NL-OMON27256
Lead Sponsor
Academic Medical Center (AMC), Department of Hepato- and Gastroenterology
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

1. Patients in the age of 18-85 years with HGD or EC in a BE.

Exclusion Criteria

1. Patients with a Barrett's segment >12 centimeters.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary clinical outcome parameters assessed at t=6 and t=12 months:<br /><br>1. Rate of total histological eradication of HGD and EC<br /><br>2. Rate of total endoscopic eradication of Barrett's mucosa<br /><br>3. Rate of total histological eradication of Barrett's mucosa
Secondary Outcome Measures
NameTimeMethod
Secondary outcome parameters:<br /><br>1. Acute and late complications of ER and RFA<br /><br>2. Percentage of surface regression of Barrett's epithelium<br /><br>3. Number of treatment sessions required to eradicate all Barrett's mucosa
© Copyright 2025. All Rights Reserved by MedPath